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To investigate the usefulness of pain-related evoked potentials (PREP) elicited by electri-
cal stimulation for the identification of small fiber involvement in patients with mixed fiber 
neuropathy (MFN). Eleven MFN patients with clinical signs of large fiber impairment and 
neuropathic pain and ten healthy controls underwent clinical and electrophysiological 
evaluation. Small fiber function, electrical conductivity and morphology were examined 
by quantitative sensory testing (QST), PREP, and skin punch biopsy. MFN was diagnosed 
following clinical and electrophysiological examination (chronic inflammatory demye-
linating neuropathy: n =  6; vasculitic neuropathy: n =  3; chronic axonal neur opathy: 
n = 2). The majority of patients with MFN characterized their pain by descriptors that 
mainly represent C-fiber-mediated pain. In QST, patients displayed elevated cold, warm, 
mechanical, and vibration detection thresholds and cold pain thresholds indicative of 
MFN. PREP amplitudes in patients correlated with cold (p < 0.05) and warm detection 
thresholds (p < 0.05). Burning pain and the presence of par-/dysesthesias correlated 
negatively with PREP amplitudes (p < 0.05). PREP amplitudes correlating with cold and 
warm detection thresholds, burning pain, and par-/dysesthesias support employing 
PREP amplitudes as an additional tool in conjunction with QST for detecting small fiber 
impairment in patients with MFN.
Keywords: mixed fiber neuropathy, pain-related evoked potentials, aδ- and c-fibers, neuropathic pain, burning 
pain, quantitative sensory testing
inTrODUcTiOn
Painful polyneuropathies of different origin often affect large- and small-nerve fibers (1, 2) and are 
therefore termed mixed fiber neuropathies (MFN). Evaluating small fiber impairment can facilitate 
the differential diagnosis of painful MFN. Familial amyloid polyneuropathy is an example of MFN 
that may initially be asymptomatic (3) and where assessment of small fiber function may allow an 
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early diagnosis. Small fiber tests could be appropriate in clinical 
course and analyzing therapy efficacy (4). The latter is of particu-
lar importance, since efficacious pharmacotherapy is disposable 
for several acquired neuropathies (5). Small thinly myelinated 
as well as unmyelinated nerve fibers (Aδ- and C-fibers) can be 
assessed via neurological examination and quantitative sensory 
testing (QST) (6). However, both methods are subjective and very 
dependent on patients’ cooperation. Since standard nerve con-
duction studies fail to measure the impairment of small-caliber 
nerve fibers, alternative objective means are needed. Nociceptive 
laser-evoked potentials (LEP) and contact heat-evoked potentials 
(CHEP) are suitable electrophysiological methods to detect 
functional impairment of small fibers in painful MFN (7). 
However, LEP and CHEP have drawbacks in clinical routine 
such as expensive equipment and complex procedures (8). The 
recording of electrically elicited pain-related evoked potentials 
(PREP) via concentric electrodes (9) is a useful, non-invasive, 
and handy method to detect small fiber impairment in early 
diabetes (10), human immunodeficiency virus (HIV) associated 
neuropathy (11), Fabry disease (12), and fibromyalgia syndrome 
(13). Neuropathic pain, pathological sural nerve conduction, and 
pathological PREP have been obtained in patients with hepatitis 
C- and HIV infection-associated sensory neuropathies (11, 14). 
PREP are thus suitable for detecting small fiber involvement in a 
variety of conditions characterized by small fiber pathology.
Painful MFN is a neuropathy encountered frequently in clini-
cal routine, for example in patients with chronic inflammatory 
demyelinating neuropathy (CIDP). CIDP patients often have 
small fiber impairment in addition to large fiber affection (15). 
Neuropathic pain in large fiber neuropathy patients indicates but 
does not ascertain the involvement of small nerve fibers (16, 17). 
To accelerate diagnosis and treatment, and to monitor the time 
course of small nerve fiber degeneration or pharmacotherapeutic 
efficacy in MFN patients, a simple and objective tool to determine 
small fiber involvement is required.
We therefore investigated the usefulness of PREP in assessing 
small fiber involvement in painful MFN. We additionally utilized 
QST as a standard instrument to retrieve small fiber function in 
neuropathy patients and compared PREP and QST data in MFN. 
We hypothesized that PREP amplitudes would be reduced and 
PREP latencies delayed particularly when elicited from the feet 
in patients with additional small fiber affection.
BacKgrOUnD
Patients and subjects
In this study, eleven patients with painful MFN (median 
age  =  61  years, range: 37–83  years, three females and eight 
males) were prospectively enrolled in parallel to the recruitment 
of healthy control subjects. The diagnosis was made when clinical 
signs of large fiber affection as well as neuropathic pain coincided. 
The recruitment of patients was performed between 2009 and 
2012 at the Department of Neurology, University of Würzburg. 
Inclusion criteria consist of female and male patients at the age 
of ≥18 years, confirmed diagnosis of painful motor or sensory 
polyneuropathy (by medical report, neurological examination, 
standard neurophysiology). Exclusion criteria were: pain of 
other than neuropathic origin (e.g., dermatologic, orthopedic) or 
abnormal blood investigations not related to the neuropathy. A 
robust and reproducible PREP response was a prerequisite for 
including MFN patients in our study, as we were dedicated to 
delineating the differences between PREP latencies and ampli-
tudes in patients and controls.
We compared our data with those from ten healthy age- and 
gender-matched controls recruited during our study (median 
age = 55 years, range: 26–67 years; four females and six males). 
Inclusion criteria for control subjects comprised the following 
items: ≥18 years, unremarkable sural nerve conduction, no neu-
ropathy and no report of pain (neuropathic pain or other causes 
of pain). The age and gender did not vary significantly between 
patients and control subjects (p > 0.05 each). The performance of 
the study was in agreement with the Declaration of Helsinki. The 
study was authorized by the Würzburg Medical Faculty Ethics 
Committee. Recorded informed consent was received from all 
participants of the study.
neurological investigation, Pain and 
Depression Questionnaires, neuropathy 
scales
Every patient was subject to a neurological examination and was 
investigated by employing the German translations of pain and 
depression questionnaires as well as neuropathy scales. Severity 
of neuropathy was estimated using a variation of the Neuropathy 
Deficit Score (NDS) and the Neuropathy Symptoms Score (NSS) 
(18, 19). The Neuropathic Pain Symptom Inventory (NPSI; 
24-h recall) (20, 21) assesses neuropathic pain characteristics 
and intensity; the resulting sum score goes from 0 (no pain) 
to 1 (maximum pain). The McGill pain questionnaire (22) was 
employed to characterize patients’ pain by distinct affective and 
sensory descriptors. Patients’ answers to each of the 78 questions 
ranged between 0 (inappropriate) and 4 (fully appropriate). To 
discriminate between Aδ- and C-fiber excitation attributed pain, 
a rating test utilizing the adjectives “dull,” “pressing” and “prick-
ing” from the McGill pain questionnaire was applied according to 
Beissner (23). Pain was attributed to C-fiber excitation if the sum 
of selecting “dull” or “pressing” was higher than that of choos-
ing “pricking” (23). Pain magnitude (score based on three pain 
intensity items) and impact of pain (score of three items on pain 
perturbation with everyday life activities) was investigated by the 
Graded Chronic Pain Scale (GCPS; an altered version consisting 
of a 4-week recall) (24).
To additionally identify potential depressive symptoms, we 
utilized the Center for Epidemiologic Studies Depression Scale 
(“Allgemeine Depressionsskala,” ADS; 1-week recall) (25). The 
maximum ADS score is amounted to 60; a total score ≥  16 is 
expected to be relevant in clinical practice.
To diagnose CIDP the Inflammatory Neuropathy Cause and 
Treatment (INCAT) criteria (26) were applied; the EFNS/PNS 
criteria were used to diagnose non-systemic vasculitic neuropa-
thy (27).
Quantitative sensory Testing
All patients and healthy controls underwent QST. Following 
current recommendations (28–31), we log-transformed the QST 
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parameters and calculated z-scores, which allows normalization 
of the patient and control data to the data of the controls (mean 
and SD), i.e., also the data of the ten controls were referenced to 
themselves.
Parameters
We performed QST in each study participant on the dorsum of the 
foot following the standardized protocol of the German Research 
Network Neuropathic Pain (Deutscher Forschungsverbund 
Neuropathischer Schmerz, DFNS) and using a calibrated device 
(Somedic, Hörby, Sweden) (28, 29). We assessed the succes-
sive determinants: cold detection threshold (CDT), cold pain 
threshold (CPT), warm detection threshold (WDT), heat pain 
threshold (HPT), capability to identify temperature alterations 
(thermal sensory limen, TSL), mechanical detection threshold 
(MDT), mechanical pain sensitivity (MPS), mechanical pain 
threshold (MPT), pressure pain threshold (PPT), and vibration 
detection threshold (VDT).
In brief: for CDT and HDT, a thermode was positioned above 
the dermis and the temperature lowered or raised starting at 32°C 
(min. 10°C, max. 50°C). Each control subject or patient pushed a 
knob when the temperature he or she sensed was cold or warm, 
respectively. CPT and HPT were assessed accordingly. TSL was 
determined by alternately changing the thermode’s temperature 
beginning at 32°C; the subject pushed a button to indicate 
when a change in temperature was felt. MDT was determined 
by stimulating the skin with calibrated von Frey filaments; the 
examination started with a von Frey filament of 16 mN and the 
intensity reduced or increased in the filament being sensed by 
the subject defining the MDT (range 0.25–512 mN). Calibrated 
pinpricks (range 0.25–512  mN) were applied to determine the 
MPT; to determine the MPS, the subject was stimulated with a 
pin-prick and thereafter with a brush, a Q-tip or a cotton ball; the 
subject then rated the degree of strength of the pinprick stimulus 
on a chart from 0 to 100. The VDT was determined using a tuning 
fork. A calibrated algesiometer (Wagner Instruments, USA) was 
used to assess the PPT.
Assessment
For group analysis, patients’ data were compared with data from 
10 healthy control subjects following the same protocol at our 
department. According to current recommendations (28–31), 
QST raw values were log-transformed to reach normal distribu-
tion (CDT, MDT, MPS, PPT, TSL, WDT). The CPT, HPT, and 
VDT parameters were not log-transformed (28, 29), as the ratio 
for raw data to log-transformed data did not cross a factor of three, 
and as one prerequisite for log-transformation (i.e., determina-
tion of the exact zero-threshold of the respective parameter) was 
unfulfilled (29). With these data, we calculated a z-score utilizing 
the formula: z-score [(value of the patient - mean value of control 
subjects)/SD of control subjects]. Calculating the z-score allows 
the normalization of patient data to the control group. Positive 
z-scores reveal a gain of function whereas negative z-scores 
point to a loss of function in comparison to the controls. Since 
in this formula the controls’ QST values are normalized to their 
own mean and SD, the controls’ QST z-score values result in 
zero with a SD of one. Since the MPS examination may result 
in “zero,” we applied the Bartlett procedure (31, 32) and added 
a constant of 0.1 to the MPS results for statistical reasons (33). 
Z-values below or above ±1.96 were determined as aberrant 
(30, 34).
For individual assessments of QST results, we used pub-
lished normative data (30). The controls’ QST values were 
within the extent of released QST data from healthy control 
groups (12, 13, 35, 36).
electrophysiological assessment
All patients and healthy controls underwent nerve conduction 
studies. The right sural and tibial nerves in patients and the right 
sural nerves in healthy controls were examined utilizing electrodes 
according to standard procedures (37) to determine large fiber 
polyneuropathy. Findings were compared with our laboratory 
normal values for adults. Our laboratory normal values consist 
of an antidromic sural nerve action potential (SNAP) amplitude 
≥10 μV for age <65 years and ≥5 μV for age >65 years. The nor-
mal values for the sural nerve conduction velocity (NCV) were 
>40  m/s for all age groups. The tibial nerve compound motor 
action potential (CMAP) was composed of values ≥10 mV and 
the tibial NCV ≥40 m/s for all age groups.
Pain-related evoked Potentials
All patients and healthy controls underwent PREP derived from 
Cz via a needle electrode sited subcutaneously and referenced 
to connected ear lobes (A1-A2, international 10–20 system) 
as formerly mentioned in detail (13). Signal Software (Version 
2-16, Cambridge Electronic Design, Lt., Cambridge, UK) was 
used. The potentials were elicited via electrical stimulation with 
a constant current stimulator (DS7A, Welwyn Garden City, UK) 
at the right and left foot (dorsum) employing planar concentric 
electrodes attached to the skin (Inomed Medizintechnik GmbH, 
Lübeck, Germany). This stimulation paradigm consists of 20 
triple pulses at twofold intensity of each pain threshold lasting 
0.5 ms, a triple pulse interval of 5 ms and random inter-stimulus 
interval of 15–17 s. The recording set-up comprises the following 
adjustments: gain: ×5000, bandwidth: 1 Hz–1 kHz, digitalization 
sampling rate: 2.5  kHz and sweep length: 400  ms. Single pain 
threshold was ascertained by stimulating twice with current 
intensities that rose and fell until the person remarked a pin-prick 
perception. The MATLAB software (Version 7.7.0471, Ismaning, 
Germany) was utilized to survey averaged curves (n = 20 single 
sweeps) for reproducible N1- (i.e., first negative peak), P1- (i.e., 
subsequent positive peak) latencies, and peak-to-peak amplitudes 
(PPA). Every curve was analyzed off-line via an examiner blinded 
to the diagnosis on coded data files. Recordings containing 
technical or biological artifacts were excluded from the analysis. 
Only those recordings were included that showed robust and 
reproducible potentials. Additional exclusion criteria for PREP 
recordings were: history of epilepsy, cardiac pacemakers, and 
deep brain stimulators.
skin Biopsies
All patients underwent skin punch biopsies with a size of 5 mm 
(punch device: Stiefel, Offenbach, Germany) obtained to assess 
intra-epidermal nerve fiber density (IENFD). The locus for the 
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removal of the biopsies was the lower extremity 10 cm proximal 
to the lateral malleolus. The skin probes were treated as speci-
fied formerly (38). Immunoreactions of the individual sections 
were caused by antibodies to protein-gene product (PGP) 9.5 
(Ultraclone limited, Isle of Wight, UK, primary antibody; 1:800). 
The PGP 9.5 antibodies were combined with goat anti-rabbit 
IgG marked with cyanine 3.18 fluorescent sample (Amersham, 
USA, Cy3, secondary antibody; 1:100) (12). The IENFD was 
determined by an investigator blinded to the individual sample’s 
identification according to released approaches (39).
statistical analysis
We used Statistica 64 10 (Copyright 1984–2011, Tulsa, OK, 
USA) for statistical analysis and Sigma Plot 11.0 for Windows 
(Copyright 2008, San Jose, California, USA) for graph creation. 
Normally distributed data was subjected to the Shapiro–Wilk 
test. To compare data without normal distribution, we applied 
the non-parametric Mann–Whitney U test, and the parametric 
student’s t-test to compare data with normal distribution. Data 
without normal distribution are shown as median and range 
(demographic data, questionnaires, sural nerve electrophysiology 
data), whereas data that show a normal distribution are illustrated 
as mean ± SD (PREP as well as QST data). For comparison with 
previously published data, the McGill pain questionnaire results 
are depicted as mean ± SD. For correlation analysis, the Pearson 
Product Moment correlation was utilized. The level of significance 
was set to p < 0.05.
resUlTs
Questionnaire results, clinical Findings, 
and standard nerve conduction results
Our study cohort’s demographics, neuropathy scale scores, 
questionnaire results, and electrophysiology data are sum-
marized in Table 1. Diagnoses and characteristics documented 
during the neurological examination are listed in Table S1 in 
Supplementary Material. Eleven patients with neuropathic pain 
(i.e., pain of ≥4/10 on a numeric rating scale, NRS) and signs of 
large-fiber involvement were classified as patients with painful 
MFN. The controls comprised ten healthy subjects from our 
department not presenting any neuropathy, neuropathic pain, or 
other causes of pain. The patient group consisted of six patients 
with CIDP (26), three patients with vasculitic neuropathy (27), 
and two patients with chronic axonal neuropathies. Neurological 
examination of the lower limb revealed pathological findings in 
all patients, whereas the healthy controls revealed no clinical 
abnormalities: 11/11 (100%) patients reported hypoesthesia 
to touch, 6/11 (54%) patients had thermal hypoesthesia, 11/11 
(100%) patients had pallhypoesthesia, 7/11 (64%) patients 
presented pareses, and 10/11 (91%) patients had hyporeflexia. 
Autonomic dysfunction was present in 3/11 (27%) patients. One 
to two patients each (9–18%) reported disturbance in micturi-
tion or nycturia, cardiac arrhythmia, diarrhea, erectile dysfunc-
tion, and esophageal dysmotility. Nerve conduction studies of 
the tibial nerve revealed reduced CMAP in 10/11 (91%) patients 
and slowed NCV in 9/11 (82%) patients. Either the CMAP or 
NCV was abnormal in all patients. Electrophysiological assess-
ment of the sural nerve (Table  1) showed reduced SNAP in 
4/6 (67%) and no SNAP in 1/6 (17%) patients aged <65 years 
and reduced SNAP in 4/5 (80%) and no SNAP in 1/5 (20%) of 
patients aged >65 years. NCV of the sural nerve was abnormal 
in 4/11 (36%) patients. In contrast, the control subjects’ sural 
nerve conduction examinations were normal. 7/11 (64%) of 
patients received continious analgesic treatment (pregabalin 
n =  5, gabapentin n =  2), whereas the controls received no 
analgesic therapy.
QsT revealed large and small Fiber 
impairment
The detection thresholds of MFN patients as well as control 
subjects are illustrated in Table S2 in Supplementary Material. 
MFN patients had more elevated CDT and WDT than the 
control subjects (p  <  0.05, Figure  1) translating to reduced 
cold and warm detection capacities and indicating functionally 
impaired Aδ- and C-fibers. MFN patients thus displayed warm 
and cold hypoesthesia compared to the controls. Furthermore, 
patients’ MDT and VDT were higher than those of controls 
(p < 0.05, Figure 1). These alterations suggest impaired Aß-fiber 
function and can be termed mechanical hypoesthesia compared 
to the controls. The increased HPT in MFN patients (p < 0.05 
vs. controls, Figure 1) is compatible with impaired small fiber 
dysfunction and is called heat hypoalgesia. In healthy control 
subjects, the QST values fell within the confidence interval 
(± 1.96), indicating normal values.
TaBle 1 | Demographic, questionnaire, and neurophysiological data of 
patients with mixed fiber neuropathy and controls.
MFn 
patients
controls p-value
Demographic data
Number (male, female) 11 (8, 3) 10 (6, 4) ns
Median age years (range) 61 (37–83) 55 (26–67) ns
Median disease duration in years 
(range)
2 (0.1–4.5)
Questionnaires
Current pain intensity (NRS; 0–10) 3 (0–7) 0 p < 0.05
Median NPSI sum score 0.23 
(0.0–0.65)
0 p < 0.05
Median GCPS sum score (intensity) 53.3 (37–73) 0 p < 0.05
Median GCPS sum score 
(impairment)
1.5 (0–5) 0 p < 0.05
Median ADS score 26 (0–37) 0 p < 0.05
Median NDS sum score (0–272) 42 (20–67) 0 p < 0.05
Median NSS sum score (0–18) 5 (0–12) 0 p < 0.05
electrophysiology
sural nerve
Sensory nerve action potential (μV) 4.7 (0–17.1) 21.2 (9–37.2) p < 0.05
Nerve conduction velocity (m/s) 41 (0–46.1) 52.9 (44–56.5) ns
ADS, Allgemeine Depressionsskala; GCPS, Graded Chronic Pain Scale; MFN, mixed 
fiber neuropathy; NDS, Neuropathy Disability Scale; NPSI, Neuropathic Pain Symptom 
Inventory; ns, not significant; NSS, Neuropathy Symptom Scale; NRS, Numerical 
Rating Scale.
TaBle 2 | Pain-related evoked potentials elicited at the foot and stimulus 
intensity data of patients and controls.
Parameter MFn patients controls p-value
N1 latency (ms) 176 ± 47 162 ± 31 0.46
P1 latency (ms) 228 ± 44 210 ± 47 0.39
PPA (μV) 30 ± 15 39 ± 31 0.45
Current intensity (mA) 2.07 ± 0.37 1.8 ± 0.4 0.15
ns, not significant; PPA, peak-to-peak amplitudes.
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altered Thermal Perception in Patients 
with MFn correlates with PreP 
amplitudes
Stimulus intensities used to elicit PREP from the feet were not 
different between MFN patients and control subjects (Table 2). 
We analyzed pooled data (N1, P1, and PPA as well as stimulus 
intensities) from both sides of the lower legs since no side dif-
ference had been observed. N1 and P1 latencies as well as PPA 
amplitudes of PREP were not different between MFN and control 
subjects, except for a tendency toward prolonged N1/P1 latencies 
and reduced PREP amplitudes in MFN (Table 2; Figure 2 shows 
a representative example of a PREP trace of a control subject). 
Analysis of PREP parameters in the largest subgroup of CIDP 
patients (n =  6) compared to controls revealed no intergroup 
difference. Between PREP PPA induced at the feet and thermal 
perception thresholds (CDT, WDT, TSL) of MFN patients a 
positive correlation was encountered (Figures 3A–C). We noted a 
positive correlation for CDT in MFN patients (r = 0.71, p < 0.05, 
Figure 3A), as well as for WDT (r = 0.63, p < 0.05, Figure 3B) 
and TSL (r = 0.67, p < 0.05, Figure 3C). We found no correla-
tion for CDT, WDT, and TSL with PREP PPA in control subjects 
FigUre 1 | sensory profile of patients with mixed fiber neuropathy 
(MFn) and controls obtained by quantitative sensory testing (QsT). 
The bar graphs depict the z-scores at the dorsal foot in MFN patients 
contrasted to healthy control subjects. Healthy controls are shown by white 
bar graphs, whereas MFN patients are represented by black bar graphs. The 
z-scores of healthy controls are zero with a SD of one due to the calculation 
of z-score (see methods). This is the reason why the white bar graphs are not 
seen and disappear in the zero-line. z-scores < 0 indicate a loss of function, 
z-scores > 0 exhibits a gain of function. MFN displays impaired cold (CDT), 
warm (WDT), mechanical (MDT), and vibration detection thresholds (VDT) as 
well as cold pain thresholds (CPT) compared to controls (p < 0.05) indicating 
deafferentation of small and large fibers. NB: Patients’ CPT was 10°C which 
is the cut-off value for CPT assessment during QST. Therefore, the CPT value 
does not have an error bar. Abbreviations: CPT, cold pain threshold; HPT, 
heat pain threshold; ability to detect temperature changes (thermal sensory 
limen, TSL); MPT, mechanical pain threshold; MPS, mechanical pain 
sensitivity; PPT, pressure pain threshold (PPT); VDT, vibration detection 
threshold. Data are expressed as mean and SD.*p < 0.05.
(Figures  3D–F). CPT, and HPT z-scores as functions of small 
fibers and MDT, MPT, VDT, and PPT z-scores reflecting large 
fiber function did not correlate with PREP PPA in patients with 
MFN or in the controls. Moreover, we detected no correlations 
between PREP, sural nerve NCV, and sural nerve SNAP amplitude 
and controls. Burning pain quality and the presence of par- or 
dysesthesias assessed by the respective NPSI subscores correlated 
negatively with PREP PPA in MFN patients (r = −0.68, p < 0.05, 
Figures 4A,B). We observed no correlation between paroxysmal 
and evoked pain and PREP PPA in patients with MFN. Moreover, 
IENFD showed no correlation with the intensity of burning pain 
and the existence of par- or dysesthesias in the NPSI subscores 
of patients with MFN (Figures 4C,D). Pain intensity elicited by 
the electrical stimulus did not correlate with the PREP PPA in 
MFN patients and controls. Furthermore, the IENFD failed to 
correlate with either PREP latencies or amplitudes. In particular, 
we observed no correlation between the loss of IENFD in distal 
skin biopsies and burning pain or with par- and dysesthesias in 
MFN patients. In addition, we found no correlation between 
electrical stimulus intensity and IENFD.
Analyzing the NPSI subscores, burning pain was the most 
frequently reported pain quality in patients with MFN (64%), 
whereas less than half of the patients experienced pressure, evoked, 
or paroxysmal pain (36–47%; see Table S3A in Supplementary 
Material). In contrast, our healthy control subjects reported no 
burning, pressure, evoked or paroxysmal pain. In the McGill 
pain questionnaire, MFN patients characterized their pain using 
sensory and affective pain descriptors, whereas the controls 
reported no pain (see Table S3B in Supplementary Material). To 
define the predominance of Aδ- or C-fiber-mediated pain, the 
total amount of the “dull” or “pressing” pain descriptor selec-
tions was calculated from the McGill pain questionnaire data 
(23). This sum was higher than that of the selection “pricking” 
pain in 8/9 MFN patients with CIDP and vasculitic neuropathy 
who had completed the questionnaire correctly, indicative of 
C-fiber-mediated pain (2/11 patients refused to fill in the McGill 
questionnaire).
DiscUssiOn
Our results demonstrate that, in addition to QST, PREP amplitudes 
may provide a useful parameter reflecting functional small fiber 
impairment in patients with painful MFN. This observation is 
underpinned by the strong correlation among increased thermal 
perception thresholds and reduced PREP amplitudes in patients 
with MFN, and by the correlation between ongoing burning pain 
as well as par- and dysesthesias and reduced PREP amplitudes.
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Similar results have been obtained using other methods in 
small fiber neurophysiology. Nociceptive N2/P2 latencies were 
delayed and CHEP and LEP amplitudes reduced or even absent in 
MFN compared to healthy controls (7). The N2/P2 amplitude of 
LEP was reduced in patients with Charcot-Marie-Tooth disease 
type 1A (40). Two studies showed prolonged N1/P1 latencies and 
reduced PREP amplitudes in 13 patients with hepatitis C versus 
28 healthy controls and nine patients with HIV-associated MFN 
compared to nine controls (11, 14). In our study, we detected 
neither prolonged N1/P1 latencies nor reduced PREP amplitudes 
in MFN patients compared to controls. This may be due to meth-
odological differences (CHEP, LEP vs. PREP) and cohort size, and 
to our patient group’s heterogeneity.
Our MFN cohort consisted of different diagnostic subgroups 
(CIDP, vasculitic neuropathy, chronic axonal neuropathy). It 
is known that the type of neuropathy can affect cerebral pain-
associated potentials; e.g., LEP may be absent in metabolic or 
toxic neuropathies (41). Thus, future large-scale studies enrolling 
patients from different MFN subgroups are necessary to deter-
mine whether the trend toward prolonged PREP latencies and 
reduced amplitudes is relevant in some types of MFN and masked 
by other subgroups of MFN patients.
Moreover, due to the small sample size of cohorts, demo-
graphic factors such as gender and age cannot be investigated by 
this study. It is of great interest to determine the influence of these 
factors on PREP parameters in a future large-scale study.
Due to the short anode-to-cathode distance design of the con-
centric electrode nociceptive afferents in the superficial skin are 
activated. By this electrode arrangement, a high current intensity 
is gained when choosing low current stimulation. Furthermore, 
the electrical stimulation caused a pin-prick sensation that is a 
phenomenon associated with the excitation of Aδ -fiber nocicep-
tors (42–44), and the NCVs achieved by stimulating these concen-
tric electrodes fall within the range of Aδ-fibers (10, 12, 45, 46). 
No PREP were detected at up to 2.5 mA of electrical stimulation 
FigUre 2 | a representative trace of a PreP recording in a control subject. The figure shows an example of a representative PREP curve from a healthy 
control subject. The N1 and P1 latency are indicated by arrows; the peak-to-peak amplitude is indicated by a two-sided arrow.
intensity after topical application of lidocaine, which leads to a 
selective loss of thermal and pain sensation, but does not affect 
tactile sensation (47). These findings suggest that PREP are medi-
ated by small-caliber nerve fibers (47). The response of the blink 
reflex was inhibited by 90% after topical application of lidocaine, 
indicating that the blink reflex response is contaminated by the 
co-activation of Aß-fibers by 10% (9). Co-activation of Aß-fibers 
can be induced by the concentric electrode (48, 49) indicated by 
latency gaps between PREP and LEP that are larger than the ther-
moreceptor activation time of 40 ms (48, 50). However, in this 
study, the amplitudes, morphology, and topographic localization 
were similar between PREP and LEP (48) suggesting that PREP 
amplitudes might be the more specific nociceptive marker than 
PREP latencies. The coactivation of Aß-fibers might be caused 
by employing a current intensity between 3 and 5  mA applied 
via the concentric electrode (49). Therefore, particular care must 
be taken to avoid additional Aß-fiber activation (e.g., by keeping 
stimulus intensities below 2.5 mA) during PREP measurements 
that are unnecessary when applying LEP (48). In our study, the 
electrical stimulation intensity was tuned below 2.5 mA, so that 
large and medium-sized fibers might have been unspecifically 
stimulated to a small but irrelevant extent.
Therefore, this factor probably does not account for the lack of 
a difference between our patients’ and controls’ PREP parameters. 
The characterization of late components of PREP needs future 
studies. This may help to differentiate between the excitation of 
different fiber types similar to the reported early and late compo-
nents of LEP indicating Aδ- or C-fiber excitation (51).
Another issue is the potential influence of analgesic drugs on 
PREP parameters. As experimental in  vitro evidence suggests, 
nociceptive transmission in the dorsal horn is altered by anticon-
vulsant drugs such as gabapentin and pregabalin (52, 53); human 
studies showed inhibitory effects of standard analgesic drugs on 
cortical pain potentials elicited by electrical stimulation (54). Thus, 
we cannot exclude a small inhibitory influence of long-term use of 
FigUre 4 | correlations between burning pain and abnormal 
sensation as well as pain-related evoked potential (PreP) amplitudes 
and intraepidermal nerve fiber density. Negative correlation between 
PREP peak-to-peak amplitudes (PPA) and burning pain in the Neuropathic 
Pain Symptom Inventory (NPSI) subscore (r = 0.68) in mixed fiber neuropathy 
(MFN) patients is shown in (a). Similar negative correlations appeared 
between PPA and abnormal sensations in the NPSI subscore [r = 0.68, (B)]. 
However, intra-epidermal nerve fiber density (IENFD) and burning pain in (c) 
and abnormal sensation in the NPSI subscore in (D) revealed no significant 
correlations. *p < 0.05
FigUre 3 | correlations between pain-related evoked potential 
(PreP) amplitudes and thermal perception in patients with mixed 
fiber neuropathy (MFn) and controls. Correlations between PREP 
peak-to-peak amplitudes (PPA) recorded after electrical stimulation at the feet 
and quantitative sensory testing (QST) parameters are shown (cold detection 
threshold, CDT; warm detection threshold, WDT; thermal sensory limen, TSL). 
PREP peak-to-peak amplitude (PPA) correlated positively with CDT z-scores 
[r = 0.71, (a)], WDT z-scores [r = 0.63, (B)] and TSL z-scores [r = 0.67, (c)] 
in MFN patients (a–c). No correlations were found in control subjects (D–F). 
*p < 0.05
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anticonvulsants with analgesic properties on PREP parameter in 
our study. However, we do not estimate a relevant effect affecting 
our results as these anticonvulsants are no direct analgesic drugs 
and do not block nociceptive transmission within the spinal cord. 
MFN can be characterized by QST in addition to examining nerve 
conduction and clinical symptoms. Increased mechanical (MDT), 
thermal (CDT, WDT), and vibration detection thresholds (VDT) 
imply the impairment of small and large nerve fibers (28, 29). The 
relationship between reduced PREP amplitudes and increased 
CDT (more pronounced than WDT and TSL) highlights PREP 
amplitudes as a function of Aδ- more than C-fibers. PREP ampli-
tudes in MFN patients may thus be suitable for clinical application 
when pharmacotherapy or the MFN time course needs to be 
evaluated, although these correlations are not turning to account 
for a single patient. The relationship between PREP amplitudes 
and thermal perception is only detectable under pathological, 
not healthy conditions. This may indicate that the small fiber 
degeneration in skin alters both Aδ-mediated pain processing 
and thermal perception mediated by both Aδ- and C-fibers to 
a similar degree. Therefore, in pathological conditions like those 
that MFN patients experience, PREP are sensitive markers of 
small nerve fiber degeneration. Concordant with these findings, 
we did not detect any correlations between PREP amplitudes and 
QST parameters that reflect large fiber dysfunction such as VDT 
and MDT. Moreover, QST parameters that reveal C-fiber function 
such as HPT did not correlate with PREP amplitudes. This lack of 
correlation appears to reveal a potential role of PREP amplitudes 
in assessing primarily Aδ-fiber function. The correlation between 
PREP amplitudes and QST parameters reflecting small fiber 
dysfunction across different MFN subgroups in a small cohort 
supports PREP as a useful instrument for assessing small fiber 
dysfunction in addition to QST. Recording PREP at the feet is less 
time-consuming than the QST standard protocol, which would 
make easy administration in clinics potentially relevant in follow-
up situations after pharmacotherapy or to evaluate therapeutic 
efficacy. Furthermore, as disturbances of thermal perception 
accessible by combining QST and PREP often precede large fiber 
dysfunction in polyneuropathies (55, 56), PREP and QST may 
make early diagnosis more feasible.
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The absent correlation between skin biopsy results and PREP 
parameters is in agreement with antecedent reports (12, 13). This 
lack of correlation is most likely based on the fact that PREP pre-
dominantly measure Aδ fibers, whereas the intra-epidermal nerve 
fibers cover mostly C-fibers. In addition, PREP and skin biopsies 
were not obtained from exactly the same location (IENFD: lower 
leg, 10 cm upstream to the lateral malleolus; PREP: foot dorsum).
One reason why burning pain revealed no correlation with the 
IENFD in MFN patients might be that preserved C-nociceptors 
may cause spontaneous ectopic discharges resulting in pain 
(57–59). In a LEP study investigating patients with painful MFN 
of different origin, an inverse correlation was reported between 
LEP amplitudes and spontaneous burning pain, while evoked 
pain did not correlate with LEP (60). Damage to nociceptive 
fibers that have lost their intra-epidermal terminals was assumed 
to be the underlying pathophysiological mechanism for the latter 
(60), which may also apply to our findings.
Different pain phenomena might indicate potential pain 
mechanisms in MFN patients (60, 61). This opens the avenue to 
improved therapeutic strategies based on mechanisms instead of 
etiologies. Our cohort tended to complain of burning pain sup-
posedly mediated via C-fibers (62). This finding concurs with the 
predominance of C-fiber versus Aδ-fiber-mediated pain in our 
findings from the McGill pain questionnaire in CIDP and vas-
culitic neuropathy patients (23). It is not surprising that C-fiber-
mediated pain dominates pain sensation in neuropathic pain 
states, as C-nociceptors demonstrate high spontaneous activity 
in painful neuropathies, as microneurography demonstrates (59). 
Furthermore, experimental rat models have shown that abnormal 
peripheral C-nociceptor discharges with multiple spiking due to 
altered conduction in nociceptors may account for neuropathic 
pain (57). In the MFN Guillain-Barré syndrome, IENFD was lower 
in patients without pain than in those suffering from neuropathic 
pain (17). This finding supports the notion that preserved C-fibers 
are major contributors to neuropathic pain in MFN.
cOnclUsiOn
In summary, our data suggest that PREP amplitudes may be a 
sensitive and non-invasive marker of small fiber impairment 
in painful MFN in conjunction with QST. However, it is crucial 
to endorse that the clinical diagnosis of small fiber impairment 
in MFN can only be made by performing other small fiber 
tests in addition to recording PREP. Our findings support 
PREP amplitudes as an adequate tool to measure small fiber 
conductivity in patients with MFN or for follow-up after phar-
macotherapy. Large-scale future investigations are required to 
demonstrate the utility of PREP in different subgroups of MFN 
patients as an instrument for better differential diagnosis and 
treatment.
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